119 results
8-K
EX-99.2
LSTA
Lisata Therapeutics Inc
29 Feb 24
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
4:09pm
funded (LSTA eligible for ~43% rebate on all qualified R&D expenses in AUS) Objective Corroborate Phase 1b results in a placebo-controlled study
8-K
EX-99.1
LSTA
Lisata Therapeutics Inc
29 Feb 24
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
4:09pm
and R&D partnerships. The Company expects to announce numerous clinical study and business milestones over the next two years and has projected
8-K
EX-99.1
i0y1wi
2 Nov 23
Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
4:10pm
8-K
EX-99.2
br4t5q o5
2 Nov 23
Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
4:10pm
8-K
EX-99.2
7mj53mrtir
14 Aug 23
Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
4:08pm
8-K
EX-99.1
2qub2f
14 Aug 23
Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
4:08pm
8-K
EX-99.1
mhpok6x
11 Jul 23
Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors
4:01pm
8-K
EX-99.2
64lif1l2rjs fch29w
9 May 23
Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:08pm
8-K
EX-99.2
9khzbyqp poa
30 Mar 23
Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
4:07pm
8-K/A
EX-99.3
86polh h9
4 Oct 22
Other Events
4:42pm
8-K
EX-99.1
k3qb6xwikz
15 Sep 22
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
9:16am
425
5szgc
15 Aug 22
Business combination disclosure
6:46am